» Articles » PMID: 37101036

[Individualising Antihypertensive Therapy in Patients with Diabetes. A guideline by the Austrian Diabetes Association (update 2023)]

Overview
Publisher Springer
Specialty General Medicine
Date 2023 Apr 26
PMID 37101036
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertension is one of the most important comorbidities of diabetes, contributing significantly to death and leading to macrovascular and microvascular complications. When assessing the medical priorities for patients with diabetes, treating hypertension should be a primary consideration. In the present review practical approaches to hypertension in diabetes, including individualized targets for preventing specific complications are discussed according to current evidence and guidelines. Blood pressure values of about 130/80 mm Hg are associated with the best outcome; most importantly, at least blood pressure values < 140/90 mm Hg should be achieved in most patients. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers should be preferred in patients with diabetes, especially in those who also have albuminuria or coronary artery disease. Most patients with diabetes require combination therapy to achieve blood pressure goals; agents with proven cardiovascular benefit should be used (including, besides angiotensin converting enzyme inhibitors and alternatively angiotensin receptor blockers, dihydropyridin-calcium antagonists and thiazide diuretics), preferable in single-pill combinations. Once the target is achieved, antihypertensive drugs should be continued. Newer antidiabetic medications such as SGLT-2-inhibitors or GLP1-receptor agonists have also antihypertensive effects.

References
1.
Krause T, Lovibond K, Caulfield M, McCormack T, Williams B . Management of hypertension: summary of NICE guidance. BMJ. 2011; 343:d4891. DOI: 10.1136/bmj.d4891. View

2.
Schernthaner G, Barnett A, Betteridge D, Carmena R, Ceriello A, Charbonnel B . Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010; 53(7):1258-69. PMC: 2877312. DOI: 10.1007/s00125-010-1702-3. View

3.
Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

4.
Anderson R, Bahn G, Moritz T, Kaufman D, Abraira C, Duckworth W . Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care. 2010; 34(1):34-8. PMC: 3005453. DOI: 10.2337/dc10-1420. View

5.
Sun D, Zhou T, Heianza Y, Li X, Fan M, Fonseca V . Type 2 Diabetes and Hypertension. Circ Res. 2019; 124(6):930-937. PMC: 6417940. DOI: 10.1161/CIRCRESAHA.118.314487. View